ELC Group appoints former TOPRA president

Dr Paolo Biffignandi joins ELC Group’s Advisory Board

Dr Paolo Biffignandi, former president of The Organisation for Professionals in Regulatory Affairs (TOPRA), has joined the ELC Group’s Advisory Board. ELC is a pan-European pharmaceutical regulatory affairs organisation.

Dr Biffignandi, a renowned physician, with PhDs in endocrinology and pharmacology, is a Fellow of TOPRA, as well as an Overseas Fellow of the Royal Society of Medicine (UK). He brings more than 30 years' experience in Regulatory Affairs and pharmacovigilance to ELC Group’s Advisory Board.

Commenting on his appointment, Dr Biffignandi said: 'ELC Group is the industry expert, and I'm pleased to accept this opportunity to join its Advisory Board and to contribute to its continued strategic success.'

You may also like

Regulatory

ELC Group signs €1.5m regulatory affairs contract with Chinese pharma company

Endorses its Concept to Commercialisation approach to regulatory affairs consultancy services
Regulatory

ELC Group expands corporate presence in Czech Republic

Major contract wins in China and US fuel latest move into larger premises in Prague
Regulatory

ELC Group expands its offices in Ahmedabad, India

Regulatory affairs specialist continues its growth in the country
Regulatory

ELC Group opens new office in Mumbai, India

To be headed by Pooja Raj, general manager, regulatory affairs
Regulatory

ELC Group establishes global hq in Cambridge, UK

Follows year of exceptional revenue growth for regulatory affairs organisation
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Subscribe now